
Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>



































| Assay Type | Inhibition-TR-FRET |
| Analyte | Anti-TSLP Neutralizing Antibody |
| Format | 100T/500T |
| Reactivity | Human |
| Regulatory Status | RUO |
| Sensitivity | IC50=0.2264 nM |
| Standard Curve Range | 0.0033 nM-53.33 nM |
| Assay Time | 1 hr |
| Suitable Sample Type | For Human TSLP / IL-7Rα & TSLP R Inhibitor Screening |
| Sample volume | 10 μL |
2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
| ID | Components | Size |
| FRTP012-C01 | Human TSLP Protein Europium-chelate | 100 tests/500 tests |
| FRTP012-C02 | FA Labeled Human IL-7 R alpha & TSLP R | 100 tests/500 tests |
| FRTP012-C03 | Anti-TSLP Neutralizing Antibody | 25 μg/100 tests 125 μg/500 tests |
| DB-04 | TR-FRET Sample Dilution Buffer, pH7.4 | 50 mL/100 tests & 500 tests |
| DB-05 | TR-FRET Detection Buffer, pH7.4 | 50 mL/100 tests & 500 tests |


Inhibition of Europium-chelate labeled human TSLP: FA labeled human IL-7 R alpha & TSLP R binding by Anti-TSLP Neutralizing Antibody
Premix serial dilutions of Anti-TSLP Neutralizing Antibody (1:2 serial dilution, from 8 μg/mL to 0.0005 μg/mL (53.33-0.0033 nM)) and Human TSLP Protein Europium-chelate and incubate at room temperature (20℃-25℃) for 0.5 hours. Then add FA Labeled Human IL-7 R alpha & TSLP R and incubate at room temperature (20℃-25℃) for 0.5 hours. Detection was performed with IC50 of 0.2264nM. The assay was performed according to the above-described Datasheet (QC tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
| English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Tezepelumab | AMG-157; MEDI-9929 | Approved | Amgen Inc | Tezspire | Japan | Asthma | Astrazeneca Kk | 2021-12-17 | Eosinophilic Esophagitis; Dermatitis, Atopic; Hypersensitivity; Pulmonary Disease, Chronic Obstructive; Bronchial Diseases; Hypersensitivity, Immediate; Sinusitis; Respiratory Hypersensitivity; Asthma; Lung Diseases, Obstructive; Immune System Diseases; Lung Diseases; Respiratory Tract Diseases; Nasal Polyps; Nose Diseases; Chronic Urticaria; Anaphylaxis; Carcinoma | Details |
| English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| AZD-8630 | AZD-8630; AMG-104 | Astrazeneca Plc, Amgen Inc | Details | ||
| BSI-045B | BSI-045B | Boaoxin Biotechnology(Nanjing) Co Ltd | Details | ||
| SAR-443765 | SAR-443765 | Phase 1 Clinical | Sanofi | Inflammation | Details |
| MK-8226 | MK-8226 | Merck & Co Inc | Details | ||
| ASP-7266 | UPB-101; ASP-7266 | Phase 1 Clinical | Astellas Pharma Inc, Upstream Biosciences Inc | Asthma | Details |
| QX-008N | QX-008N; QX008N | Phase 1 Clinical | Qyuns Therapeutics Co Ltd | Asthma | Details |
| HBM-9378 | SKB378; HBM-9378 | Phase 1 Clinical | Harbour Biomed, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Asthma | Details |
| GR-1802 | GR-1802 | Phase 2 Clinical | Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd | Asthma; Sinusitis; Dermatitis, Atopic | Details |
| Ecleralimab | CSJ-117; NOV-14 | Phase 2 Clinical | Novartis Pharma Ag | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
| SHR-1905 | SHR-1905 | Phase 2 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Asthma | Details |
| CM-326(Connaught Biomedical Technology) | CM-326 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Nose Diseases; Nasal Polyps; Sinusitis; Asthma; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic | Details |
This web search service is supported by Google Inc.




